Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 7:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 884 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer, Gastric Cancer, Periampullary Cancer, Melanoma, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma, Gastrointestinal Stromal Tumors
Interventions
DNX-2440
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Colorectal Cancer
Interventions
aldesleukin, ras peptide cancer vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Colorectal Cancer, Colon Cancer, Prostate Cancer
Interventions
Rating and Ranking Task, Discrete Choice Task, Balance Sheet Task
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Colorectal Cancer
Interventions
Expressive writing
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Dublin, California
Conditions
Colorectal Neoplasms
Interventions
1018 ISS immunostimulatory oligonucleotide
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Colorectal Cancer
Interventions
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
Biological · Drug · Genetic + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Colorectal Cancer
Interventions
calcium carbonate, cholecalciferol, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Dietary Supplement · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Conditions
Colorectal Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
Ad5 CEA Vaccine
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Spokane, Washington
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
Interventions
Binimetinib, Encorafenib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
San Francisco, California
Conditions
Colorectal Cancer
Interventions
erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Colorectal Cancer
Interventions
chloroquinoxaline sulfonamide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Conditions
Colon Cancer Liver Metastasis
Interventions
Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
Drug · Other
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
Vitamin E, Selenium, Vitamin E placebo, selenium placebo
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
8,094 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Conditions
Colon Cancer
Interventions
Regional anesthesia and analgesia, general anesthesia followed by opioid analgesia
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated Phase 1 Interventional Results available

Ipilimumab and Local Radiation for Selected Solid Tumors

NCT01769222
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Melanoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
Ipilimumab, Radiation therapy
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Conditions
Colorectal Cancer
Interventions
cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
Biological · Drug · Genetic + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Colorectal Cancer
Interventions
cetuximab, ramucirumab, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
255
States / cities
Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 182 more